Compare Quest Diagnostics Inc (DGX) vs Equinor ASA (EQNR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Equinor ASA — how do they compare? Quest Diagnostics Inc trades at $205.37 (market cap $22.80B), while Equinor ASA trades at $36.18 (market cap $83.20B). The key difference: Equinor ASA is far larger — about 3.6× Quest Diagnostics Inc's market cap, and Equinor ASA pays the higher dividend (4.2%). Which is the better fit depends on your goals.
| DGX | EQNR | |
|---|---|---|
Market Cap | $22.80B | $83.20B |
Sector | Health | Energy |
52-Week High | $216.02 | $42.40 |
52-Week Low | $166.42 | $22.41 |
Enterprise Value | $28.82B | $94.96B |
Dividend Yield | 1.67% | 4.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Equinor (EQNR) trades at $36.06, up 6.31% with a bullish technical outlook despite mixed earnings. The stock shows strong profitability with 37.45% gross margins and attractive valuation metrics including a P/E of 16.32 and EV/EBITDA of 2.37. Recent strategic moves include expanding Norwegian Continental Shelf operations through $410M Troll field investment and acquiring BP's Bay du Nord stake, positioning for production growth.
EQNR presents a balanced opportunity with solid fundamentals and strategic growth initiatives, though declining revenue and net income trends warrant monitoring. Analyst sentiment is mixed with 30% buy ratings, while technical indicators suggest near-term strength. Key risks include volatile energy prices and execution challenges in new projects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →
